Perhaps owing to the critical role of CCR2 in the traffic of inflammatory monocytes, CCR2 antagonists have been developed by many pharmaceutical companies for potential use in the treatment of rheumatoid arthritis, asthma, diabetes, inflammatory bowel disease and multiple sclerosis, cardiovascular diseases (173) (Tables 2, 3). The gene discussed is CCR2; the disease is cardiovascular disorder.